Libtayo (Cemiplimab-Rwlc) Patent Expiration, LOE Window & CMS Spending

Libtayo (Cemiplimab-Rwlc) by Regeneron Pharmaceuticals: Biologic BLA (Purple Book Regime), 0 AB generics, $44.2M 2024 CMS Part D & Medicaid spend, and 2 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorRegeneron Pharmaceuticals
FDA Application & PathwayB761097 (BLA)
Exclusivity / Cliff HorizonBiologic BLA (Purple Book Regime)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$44.2M
2024 Medicare Part D Spend$12.6M
2024 Medicaid Spend$31.6M
Reported Wholesale Price Change (CA SB 17)2 WAC filings (max 17.9% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Regeneron Pharmaceuticals across sibling Meru public-data platforms.